| Cellbox Solutions–EU (govt): investment, 2024– equity investment up to €10m from EIC Accelerator |
2024-01-01 |
| Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures |
2023-12-05 |
| Carmot Therapeutics–Roche: investment, 202312– acquisition $2.7b upfront + $400m milestones by Roche |
2023-12-04 |
| Evomedis–MC Services: public relations, 202311 service existent by MC Services |
2023-11-23 |
| T3 Pharmaceuticals–Boehringer: investment, 202311 acquisition of T3 Pharma for up to CHF430m by Boehringer Ingelheim |
2023-11-22 |
| Evolva–Lallemand: investment, 202311– acquisitions of operations via 100% of Evolva AG for CHF20m + CHF10m milestones by Danstar Ferment AG |
2023-11-21 |
| RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF |
2023-11-21 |
| RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains |
2023-11-21 |
| Roche–Nvidia: AI-based drug r+d, 202311– collab strategic alliance multi-year of Genentech with Nvidia using Nvidia DGX Cloud + Nvidia BioNemo |
2023-11-21 |
| NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital |
2023-11-15 |
| Glox Therapeutics–SEVERAL: investment, 202311 seed financing round £4.3m led by BIVF + Scottish Enterprise |
2023-11-14 |
| Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures |
2023-11-14 |
| Insempra–Germany (govt): grant, 202311–202610 innvoation grant €1.5m from SPRIND to advance BioTreasure prototype |
2023-11-10 |
| Valanx Biotech–Niederösterreich (govt): investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor TE |
2023-11-07 |
| Valanx Biotech–SEVERAL: investment, 202311 growth financing round €2.3m incl equity + public funding led by SkyGene |
2023-11-07 |
| Valanx Biotech–SkyGene: investment, 202311 growth financing round totalling €2.3m in equity + public funding incl new + lead investor SkyGene |
2023-11-07 |
| Valanx Biotech–SOSV: investment, 202311 growth financing totalling €2.3m equity + public funding incl existing investor SOSV |
2023-11-07 |
| Valanx Biotech–Xista Science Ventures: investment, 202311 growth financing round totalling €2.3m equity + public funding incl existing investor Xista |
2023-11-07 |
| HeartBeat.bio–SEVERAL: investment, 202311 financing round pre-Series A €4.5m with i&i Biotech Fund + Invest AG + aws + Tensor Ventures |
2023-11-02 |
| Memo Therapeutics–SEVERAL: investment, 202311 financing round Series C CHF25m led by Pureos Bioventures to complete US phase 2 study with AntiBKV |
2023-11-02 |
| Cambrium–Essential Capital: investment, 202311 seed financing round totalling €8m incl lead investor Essential Capital |
2023-11-01 |
| Cambrium–Hof Capital: investment, 202311 seed financing round totalling €8m incl co-investor Hof Capital |
2023-11-01 |
| Cambrium–Merantix: investment, 202311 existing investor Merantix with approx €3m invested? |
2023-11-01 |
| Cambrium–SEVERAL: investment, 202311 seed financing round €8m led by Essential Capital |
2023-11-01 |
| Cambrium–SNR: investment, 202311 seed financing round totalling €8m incl co-investor SNR |
2023-11-01 |
| Cambrium–Valor Equity Partners: investment, 202311 seed financing round totalling €8m incl co-investor Valor Equity Partners |
2023-11-01 |
| LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical |
2023-11-01 |
| MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets |
2023-10-30 |
| Merck (DE)–Hengrui: cancer drugs, 202310– strategic alliance €160m upfront + total up to €1.4b license HRS-1167 + option SHR-A1904 ww excl China |
2023-10-30 |
| CMBlu Energy–STRABAG: investment, 202310 equity investment €100m in connection with preferred partnership agreement |
2023-10-23 |
| FarmInsect–Bavaria (govt): investment, 202310 financing round Series A totalling €8m incl existing + co-investor Bayern Kapital |
2023-10-23 |
| FarmInsect–EU (govt): investment, 202310 financing round Series A totalling €8m incl new + co-investor EIC Fund |
2023-10-23 |
| FarmInsect–High-Tech Gründerfonds: investment, 202310 financing round Series A totalling €8m incl existing + co-investor HTGF |
2023-10-23 |
| FarmInsect–Minderoo Foundation: investment, 202310 financing round Series A totalling €8m incl new + co-investor MF Strategic Impact Fund |
2023-10-23 |
| FarmInsect–Sandwater: investment, 202310 financing round Series A totalling €8m incl new + lead investor Sandwater |
2023-10-23 |
| FarmInsect–SEVERAL: investment, 202310 financing round Series A €8m led by Sandwater |
2023-10-23 |
| FarmInsect–TU Munich: investment, 202310 financing round Series A totalling €8m incl existing + co-investor UnternehmerTUM Funding for Innovators |
2023-10-23 |
| STRABAG––CMBlu Energy: energy storage solutions, 202310– strategic collab preferred supplier agreement for SolidFlow batteries |
2023-10-23 |
| Biotech Austria–MC Services: public relations, 202310 service existent by MC Services |
2023-10-17 |
| BioNTech–MediLink Therapeutics: antibody-drug conjugates, 202310– collab + ww license excl China $70m upfront + $>1b milestones for anti-HER3 ADC |
2023-10-12 |
| Japan Tobacco–Max Planck: drug discovery, 202310– collab up to 7 years with Lead Discovery Center + its academic network |
2023-10-11 |
| AstronauTx–SEVERAL: investment, 202310 financing round Series A ¯£48m led by Novartis Venture Fund |
2023-10-09 |
| LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund |
2023-10-09 |
| United Kingdom (govt)–Siemens: PET/CT scanner, 202310–202304 supply 2 Biograph Vision Quadra PET/CT scanners by Siemens Healthineers to NPIP |
2023-10-05 |
| MIRO Analytical–Bruker: investment, 202310 majority investment €na by Bruker |
2023-10-04 |
| Orakl Oncology–SEVERAL: investment, 202310 financing round €3m led by Speedinvest with HCVC + Verve Ventures |
2023-10-04 |
| Point Biopharma–Lilly: investment, 202310– cash tender offer $1.4b by Lilly at $12.5/share |
2023-10-03 |
| Kranus Health–A Round Capital: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor A Round |
2023-10-02 |
| Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures |
2023-10-02 |
| Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF |
2023-10-02 |
| Kranus Health–Karista: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-lead investor Karista |
2023-10-02 |
| Kranus Health–SEVERAL: investment, 202310 financing round Series A expansion approx $8.5m bringing total Series A to $15m |
2023-10-02 |
| Kranus Health–Wenvest: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor Wenvest |
2023-10-02 |
| Refeyn–Alto Marketing: public relations, 202310 service existent by Alto Marketing Ltd |
2023-10-02 |
| MetrioPharm–SEVERAL: investment, 202310c financing round Series D 1st closing CHF18m |
2023-10-01 |
| Alentis Therapeutics–Kyan Technologies: drug discovery technology, 202309– collab using Optim.AI + PD3D technologies for Claudin-1 expression research |
2023-09-29 |
| Nagi Bioscience–Excellis: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-investor Excellis Holding |
2023-09-28 |
| Nagi Bioscience–imec: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor imec.xpand |
2023-09-28 |
| Nagi Bioscience–SEVERAL: investment, 202309 financing round Series A CHF12.4m co-led by Swisscanto + imec.xpand |
2023-09-28 |
| Nagi Bioscience–Verve Capital Partners: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor Verve Ventures |
2023-09-28 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl existing + co-investor ZKB |
2023-09-28 |
| Nagi Bioscience–Zürcher Kantonalbank: investment, 202309 financing round Series A totalling CHF12.4m incl new + co-lead investor Swisscanto |
2023-09-28 |
| 4SC–Optimum Strategic Communications: public relations, 202309 service existent by Optimum |
2023-09-27 |
| Kern Tec–EU (govt): investment, 202309 financing round Series A totalling €12m incl co-investor EIC Fund |
2023-09-27 |
| Kern Tec–PeakBridge: investment, 202309 financing round Series A totalling €12m incl co-investor PeakBridge Growth 2 fund |
2023-09-27 |
| Kern Tec–SEVERAL: investment, 202309 financing round Series A €12m led by Telos Impact (eventually total includes grants?) |
2023-09-27 |
| Kern Tec–Telos Impact: investment, 202309 financing round Series A totalling €12m incl lead investor Telos Impact |
2023-09-27 |
| Co.faktor–Cytel: investment, 202309 acquisition of Co.faktor GmbH by Cytel Inc |
2023-09-26 |
| Cytel–BioStrata: public relations, 202309 service existent by BioStrata |
2023-09-26 |
| Pepceuticals–Biosynth: investment, 202309 acquisition of Pepceuticals Ltd by Biosynth |
2023-09-25 |
| Point Biopharma–Eckert & Ziegler: radiopharmaceuticals, 202309–203309 supply 10y >$100m of nca lutetium-177 to Point Biopharma |
2023-09-25 |
| Traceless Materials–b.value: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor b.value |
2023-09-25 |
| Traceless Materials–GLS Bank: investment, 202309 financing round Series A totalling €36.6m incl new + co-investor GLS Bank Hamburg |
2023-09-25 |
| Traceless Materials–High-Tech Gründerfonds: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor HTGF |
2023-09-25 |
| Traceless Materials–Planet A: investment, 202309 financing round Series A totalling €36.6m incl existing + co-investor Planet A Ventures |
2023-09-25 |
| Traceless Materials–SEVERAL: investment, 202309 financing round Series A €36.6m led by UB FIGG plus other new + all existing investors |
2023-09-25 |
| Traceless Materials–Sparkassen (DE): investment, 202309 financing round Series A totalling €36.6m incl new + co-investor HaSpa |
2023-09-25 |
| Traceless Materials–SWEN Capital Partners: investment, 202309 financing round Series A totalling €36.6m incl new + co-lead investor Blue Ocean fund |
2023-09-25 |
| Traceless Materials–United Bankers: investment, 202309 financing round Series A totalling €36.6m incl new + lead investor UB FIGG |
2023-09-25 |
| CARTemis Therapeutics–Germany (govt): grant, 202309c– BMBF grant €1.3m for clinical trials with CAR T-cell therapy targeting BCMA |
2023-09-21 |
| CARTemis Therapeutics–Helmholtz: investment, 202309 existent financing from Helmholtz Association spin-off fund |
2023-09-21 |
| Mainz Biomed–MC Services: public relations, 202309 service existent by MC Services |
2023-09-20 |
| Merck (DE)–BenevolentAI: AI-based drug discovery, 202309– strategic collab up to $594m plus royalties incl low 2-digit-$m upfront |
2023-09-20 |
| Merck (DE)–Exscientia: AI-based drug discovery, 202309– collab $20m upfront + $674m milestones plus royalties |
2023-09-20 |
| Broken String Biosciences–Holtzbrinck: investment, 202309 financing round Series A totalling $15m incl existing + co-investor DvH Ventures |
2023-09-18 |
| Broken String Biosciences–SEVERAL: investment, 202309 financing round Series A $15m co-led by Illumina Ventures + Mérieux Equity Partners |
2023-09-18 |
| SHS Capital–SEVERAL: investment, 202309 final closing of SHS VI fund adding ca €50 after first close bringing total fund size to €270m |
2023-09-13 |
| Moderna–Immatics: cancer drugs, 202309– strategic r+d collab $120m upfront + >$1.7b funding + milestones + royalties combing tech platforms |
2023-09-11 |
| Grande Bio-tech–Oncgnostics: molecular diagnostics, 202309 – distribution of early cancer detection tests developed by Oncgnostics in ASEAN countries |
2023-09-05 |
| Oncgnostics–Grande Bio-tech: investment, 202309 financing round totalling €7-digit incl lead investor Grande Bio-tech Co Ltd with €7-digit investment |
2023-09-05 |
| Oncgnostics–High-Tech Gründerfonds: investment, 202309 financing round totalling €7-digit incl existing + co-investor HTGF |
2023-09-05 |
| Oncgnostics–SEVERAL: investment, 202309 financing round €7-digit led by Grande Bio-tech Co Ltd + incl bm-t + HTGF |
2023-09-05 |
| Oncgnostics–Thuringia (govt): investment, 202309 financing round totalling €7-digit incl existing + co-investor bm-t |
2023-09-05 |
| Takara Shuzo–Eppendorf: lab automation equipment, 202308– collab strategic co-marketing agreem automating Takara Bio chemistries on epMotion platforms |
2023-08-25 |
| PhenomeX–Bruker: investment, 202308–202310 acquisition cash tender offer $108m by Bruker at $1/share |
2023-08-17 |
| Bactolife–SEVERAL: investment, 202308 financing round Series A €30m led by Athos + incl Gates Foundation + Novo Holdings et al |
2023-08-08 |
| IO Biotech–SEVERAL: investment, 202308 private placement $75m with existing + new investors |
2023-08-07 |
| AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany |
2023-08-02 |
| Bind-X–Greeneering Invest: investment, 202308 financing round Series B totalling €10m incl new investor Greeneering Invest |
2023-08-01 |
| Bind-X–Heritage Group: investment, 202308 financing round Series B totalling €10m incl new investor HG Ventures |
2023-08-01 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
